BTG3 and COVID-19: In accordance, serum ANA assay showed that two out of six (33.3%) of the S protein-treated mice developed ANA autoantibodies (Figure 1E), closely mirroring the reported prevalence of ANA positivity (20-30%) in COVID-19 patients (8, 47).